Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk
about
Interleukin-22 Signaling in the Regulation of Intestinal Health and DiseaseInterleukin-1 Family Cytokines in Liver DiseasesTherapeutic Lymphoid Organogenesis in the Tumor MicroenvironmentNovel insights into the role of immune cells in skin and inducible skin-associated lymphoid tissue (iSALT)Cytokines in psoriasisIMQ Induced K14-VEGF Mouse: A Stable and Long-Term Mouse Model of Psoriasis-Like InflammationThe role of dendritic cells in autoimmunityIL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin.IL-36 receptor deletion attenuates lung injury and decreases mortality in murine influenza pneumonia.Experimental atopic dermatitis depends on IL-33R signaling via MyD88 in dendritic cells.Interleukin-36β provides protection against HSV-1 infection, but does not modulate initiation of adaptive immune responsesIL-6 as a druggable target in psoriasis: focus on pustular variants.The interleukin-1 family: back to the futureCathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36γ.Mixing Signals: Molecular Turn Ons and Turn Offs for Innate γδ T-Cells.Suppression of molecular inflammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin inflammation.Genetic and pharmacological analysis identifies a physiological role for the AHR in epidermal differentiation.Interleukin-22: immunobiology and pathology.Limited Contribution of IL-36 versus IL-1 and TNF Pathways in Host Response to Mycobacterial Infection.Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathwaysIL-6 Signaling in Myelomonocytic Cells Is Not Crucial for the Development of IMQ-Induced PsoriasisIL-36γ Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses.The role of group IIF-secreted phospholipase A2 in epidermal homeostasis and hyperplasiaUnprocessed Interleukin-36α Regulates Psoriasis-Like Skin Inflammation in Cooperation With Interleukin-1Enhanced stability of tristetraprolin mRNA protects mice against immune-mediated inflammatory pathologies.Periostin contributes to epidermal hyperplasia in psoriasis common to atopic dermatitis.Plasmacytoid dendritic cells orchestrate TLR7-mediated innate and adaptive immunity for the initiation of autoimmune inflammation.Deficiency in IL-17-committed Vγ4(+) γδ T cells in a spontaneous Sox13-mutant CD45.1(+) congenic mouse substrain provides protection from dermatitisNeutrophils in animal models of autoimmune diseaseThe severity of experimental arthritis is independent of IL-36 receptor signaling.Therapeutic antibodies that target inflammatory cytokines in autoimmune diseasesDual Roles of Group IID Phospholipase A2 in Inflammation and CancerEpidermal IL-15Rα acts as an endogenous antagonist of psoriasiform inflammation in mouse and man.Keratinocytes contribute intrinsically to psoriasis upon loss of Tnip1 function.Immune mediated shaping of microflora community composition depends on barrier siteIncreased IL17A, IFNG, and FOXP3 Transcripts in Moderate-Severe Psoriasis: A Major Influence Exerted by IL17A in Disease Severity.Imiquimod Treatment Causes Systemic Disease in Mice Resembling Generalized Pustular Psoriasis in an IL-1 and IL-36 Dependent Manner.Sex-specific control of central nervous system autoimmunity by p38 mitogen-activated protein kinase signaling in myeloid cells.Complement C3 Exacerbates Imiquimod-Induced Skin Inflammation and Psoriasiform DermatitisImiquimod has strain-dependent effects in mice and does not uniquely model human psoriasis.
P2860
Q26770224-F154D0FE-CA61-43C1-96C2-0DE15FD54F36Q26778553-17EDF587-F9A6-404F-9937-F1B9D72F7F98Q26799123-C977F9AC-32F6-4AC0-B223-9BD9FF9F0763Q28081241-ABCC1F80-1886-4D83-ACD1-B7CAFF8B5EE6Q28255491-EA3C1E97-C104-436D-B208-EAF12E8F6C17Q28551673-31D2B96D-EA1D-402A-9537-3EDDADCECD70Q30047565-E4C7E449-3924-403A-90B2-8441EE9F6276Q33723794-F667A214-544E-4805-A1E6-6B3A122135A5Q33799030-E2D03DBD-BCBE-49B9-AA32-17F729EBCBF3Q33815955-4C326532-9809-4F08-81E6-3D538ED5A742Q33918535-CC920D44-B962-4E8A-9FF1-7B9CEFD2EAC4Q34003280-3D14D9EC-EE81-495C-8FC9-72CD26B8B75BQ34391415-A11455D9-3F90-4B8C-AED0-2D742E596048Q34553191-BD62492A-10FC-4B14-A45A-82C125ED1825Q34730063-C3ACE6D3-0A50-454A-8FE2-456BC843C994Q35081002-7466BAF0-174F-45B9-B425-70557FFAE5B6Q35470109-C4798DDE-1C1B-4EB5-860E-C79E2729A91DQ35530956-52830775-A4B5-4791-A780-C514F1251530Q35623978-D25FBF9B-8151-419B-947A-4E2F098E5334Q35803992-9ECA0892-A260-4E07-95B4-3C99FA067520Q35964908-5D3F8824-C84E-4C74-BDBF-E9AE543D637EQ36070562-59C0CA98-7B5F-4962-B28B-C8E83369267AQ36180657-10075016-FEC4-46FC-B2DB-9923DE79A4A0Q36289222-BAD35598-E5B0-4B1E-88D5-241B4FF9D4BEQ36607631-7EAE95EB-F82F-4602-9F74-E8F38E190C63Q36691823-B20000BA-7574-4989-BB6D-471BEE3DFFF0Q36796084-7F126BA2-F8DB-49BB-A6B7-F7D6813BC228Q36864158-3B606420-BE5F-4576-8806-8D1418EDD0B7Q36902110-D23B74FD-90F2-4429-810E-7CCFBCC01EB4Q36903300-4EC074F6-95D3-46FF-A886-C728DE115EB5Q36958902-EFCB645F-F0A8-46ED-8996-F2CF1C988C6CQ37117284-E5C80D96-3651-4EEA-8FA1-FAFBCAABA07FQ37194962-41A025DD-1E7C-4269-AAD5-69567A0100C7Q37346779-9C99C1A2-D54A-4A1B-A12E-F0F87ADBCE22Q37452507-52374C5D-FF3B-4C0D-B384-13A293A9979FQ37500781-EBB39ED3-5534-4D3A-9CBE-9FEFEEAC7D7EQ37531803-814DE515-8200-438E-84A7-B5F8F07BA46EQ37622868-7286B3A5-CD1F-41C0-8529-5DF44F2E9CAEQ37656091-5D2B03CE-7190-47C7-B243-5165762E34C6Q37692600-6479BD65-B8BD-4753-9523-4FA56933C00D
P2860
Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk
description
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2012
@ast
im November 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2012/11/01)
@sk
vědecký článek publikovaný v roce 2012
@cs
wetenschappelijk artikel (gepubliceerd op 2012/11/01)
@nl
наукова стаття, опублікована в листопаді 2012
@uk
مقالة علمية (نشرت في نوفمبر 2012)
@ar
name
Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk
@ast
Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk
@en
Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk
@nl
type
label
Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk
@ast
Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk
@en
Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk
@nl
prefLabel
Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk
@ast
Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk
@en
Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk
@nl
P2093
P2860
P50
P3181
P356
P1476
Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk
@en
P2093
Anthony J. Coyle
Brian Abel
Esther Rosenwald
Hal Blumberg
Jean-Christoph Renauld
Luigi Tortola
Matthias Schäfer
P2860
P304
P3181
P356
10.1172/JCI63451
P407
P577
2012-11-01T00:00:00Z